
Venture capital · Early stage · Est. 2021
Cure Ventures
Boston-based life sciences venture capital firm that forms new therapeutics companies from scratch with scientist-entrepreneurs, backing them at seed and embedding experienced operators.
Investment activity
Round-by-round activity is part of PRO
Key signal this week
Is Cure Ventures right for your round?
Key stats
Fund cycle Public record
Fund vehicles on public registers (SEC adviser filings). Values are the gross assets each filing reports, not fund sizes.
Latest investments
Rounds Cure Ventures joined, from press and the firm’s own posts.
Every round Cure Ventures joined
Round sizes, Cure Ventures’s role and who invested alongside.
Notable portfolio
Portfolio and exits
Every company Cure Ventures backed and how the exits played out.
Where the money goes
Share of companies at first investment, from the rounds we track.
Investment team
Where to meet Cure Ventures
Events where Cure Ventures’s team spoke or showed up, from event programmes, press and the firm’s own posts.
Signals
Register and fund filings are free. Website, team and portfolio changes we pick up are PRO.
Founders also look at
Frequently asked questions
Cure Ventures is based in Boston, United States.
In 2021.
2 fund vehicles are on public registers (SEC adviser filings), including CURE VENTURES FUND I, L.P. and CURE VENTURES FUND II, L.P.
Stages: Seed. Sectors: Life sciences. From the firm’s own website.
Cure builds de novo biotech companies around curative technologies. It funds at seed to de-risk the science, uses genetic validation to raise the odds of success, and embeds experienced drug-development operators who work day to day alongside founders. From the firm’s own website.
Cure Ventures lists 12 portfolio companies on its website, including Aevum Therapeutics, Alessa Therapeutics, Clasp Therapeutics, Crosslink Therapeutics and Kenai Therapeutics.
Firms whose websites list some of the same companies include The Column Group, ANV MANAGEMENT, LLC and ARCH Venture Partners.
Know before Cure Ventures’s next round is announced.
PRO tracks Cure Ventures’s filings, hires and portfolio changes the day they land, alongside 3,869 other firms.